Modern aspects of the treatment of hemophilia.
The prognosis of hemophilic hemorrhages is greatly dependent on the therapy which is administered during the first three to five days. To prevent overloading of the circulation, highly active preparations of the antihemophilic factor should be available.A survey of the recently developed concentrated products of this factor and of their suitability for clinical use is presented. The authors describe their own experiences in the treatment of a number of patients with hemophilia A by administration of so-called "two-donor" fibrinogen.The effect of this "two-donor" fibrinogen was not inferior to results obtained else-where with the so-called I-O product, prepared from a much greater quantity of blood plasma.
D003029:Coagulants; D005169:Factor VIII; D005340:Fibrinogen; D006467:Hemophilia A; D006801:Humans
D003029:Coagulants; C427184:recombinant factor VIII SQ; C078147:F8 protein, human; D005169:Factor VIII; D005340:Fibrinogen
FACTOR VIII; HEMOPHILIA